Clinical Updates and Insights in Non-Hodgkin Lymphoma - prIME Oncology
eNewsletter
eNewsletter

Clinical Updates and Insights in Non-Hodgkin Lymphoma

From the 2017 Conference on Malignant Lymphoma in Lugano, Switzerland

Not a member of My prIME? Join now for instant access.

With this newsletter, stay up-to-date with the latest trial updates in non-Hodgkin lymphoma. Discussion will focus on recent results presented at the 2017 Conference on Malignant Lymphoma in Lugano, Switzerland.

eNewsletter

eNewsletter

Release Date

Release Date

Jul 11, 2017

Expiration Date

Jul 11, 2018

  • Indolent non-Hodgkin lymphoma
  • Aggressive non-Hodgkin lymphoma

This activity is designed to meet the needs of hematologists, hematologists/oncologists and other healthcare professionals involved in the treatment of patients with indolent non-Hodgkin lymphoma.

Upon completion of this educational activity, participants should be able to:

  • Evaluate best practices regarding the treatment of patients with lymphoma, including integration of novel therapeutic approaches and individualization of care

This educational newsletter is supported by a grant from Bayer HealthCare Pharmaceuticals.

Enduring Materials From a Certified Activity

This enduring material, derived from a certified live event, contains content that is evidence-based, balanced, and free of commercial bias. While the content was planned and implemented by prIME Oncology for a certified live event, this activity does not offer continuing education credit.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.